1. Home
  2. WSBCO vs HCM Comparison

WSBCO vs HCM Comparison

Compare WSBCO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WSBCO
  • HCM
  • Stock Information
  • Founded
  • WSBCO N/A
  • HCM 2000
  • Country
  • WSBCO United States
  • HCM Hong Kong
  • Employees
  • WSBCO N/A
  • HCM N/A
  • Industry
  • WSBCO Major Banks
  • HCM Biotechnology: Pharmaceutical Preparations
  • Sector
  • WSBCO Finance
  • HCM Health Care
  • Exchange
  • WSBCO Nasdaq
  • HCM Nasdaq
  • Market Cap
  • WSBCO 2.5B
  • HCM 2.6B
  • IPO Year
  • WSBCO N/A
  • HCM N/A
  • Fundamental
  • Price
  • WSBCO $25.40
  • HCM $15.40
  • Analyst Decision
  • WSBCO
  • HCM Sell
  • Analyst Count
  • WSBCO 0
  • HCM 1
  • Target Price
  • WSBCO N/A
  • HCM $13.75
  • AVG Volume (30 Days)
  • WSBCO N/A
  • HCM 46.4K
  • Earning Date
  • WSBCO N/A
  • HCM 08-07-2025
  • Dividend Yield
  • WSBCO N/A
  • HCM N/A
  • EPS Growth
  • WSBCO N/A
  • HCM N/A
  • EPS
  • WSBCO N/A
  • HCM 0.53
  • Revenue
  • WSBCO N/A
  • HCM $602,197,000.00
  • Revenue This Year
  • WSBCO N/A
  • HCM N/A
  • Revenue Next Year
  • WSBCO N/A
  • HCM $15.49
  • P/E Ratio
  • WSBCO N/A
  • HCM $5.78
  • Revenue Growth
  • WSBCO N/A
  • HCM N/A
  • 52 Week Low
  • WSBCO N/A
  • HCM $11.51
  • 52 Week High
  • WSBCO N/A
  • HCM $21.50
  • Technical
  • Relative Strength Index (RSI)
  • WSBCO N/A
  • HCM 43.51
  • Support Level
  • WSBCO N/A
  • HCM $14.99
  • Resistance Level
  • WSBCO N/A
  • HCM $16.40
  • Average True Range (ATR)
  • WSBCO 0.00
  • HCM 0.33
  • MACD
  • WSBCO 0.00
  • HCM -0.08
  • Stochastic Oscillator
  • WSBCO 0.00
  • HCM 29.08

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Share on Social Networks: